 |
|
Chemotherapy Before and After Mastectomy in Stage III Breast Cancer
Marjorie Perloff, MD;
Gerson J. Lesnick, MD
Arch Surg. 1982;117(7):879-881.
Abstract
• Seventeen patients with stage III breast cancer were treated by modified radical mastectomy preceded and followed by multiagent cytotoxic chemotherapy. The preoperative treatment resulted in a decrease in size of the primary tumor, facilitating the subsequent surgical procedure. There were no serious surgical complications. Wound healing was uneventful. Median disease-free survival time was 29 months and median survival time was 40+ months. Six of the 17 patients are living free of recurrence from more than 33 to more than 79 months after initial therapy.
(Arch Surg 1982;117:879-881)
Author Affiliations
From the Departments of Neoplastic Diseases (Dr Perloff and Surgery (Dr Lesnick), Mount Sinai School of Medicine, New York. Dr Perloff is now with Columbia University College of Physicians and Surgeons, New York.
Footnotes
Accepted for publication Feb 18, 1982.
Reprint requests to Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032 (Dr Perloff).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Neoadjuvant Endocrine Therapy
Dixon and Macaskill
Am Soc Clin Oncol Ed Book 2009;2009:39-43.
ABSTRACT
| FULL TEXT
Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial
Zhu et al.
Clin. Cancer Res. 2004;10:4639-4644.
ABSTRACT
| FULL TEXT
Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18
Wolmark et al.
J Natl Cancer Inst Monogr 2001;2001:96-102.
ABSTRACT
| FULL TEXT
Primary Systemic Therapy in Operable Breast Cancer
Wolff and Davidson
JCO 2000;18:1558-1569.
ABSTRACT
| FULL TEXT
|
